A 2.0 mg dose Semaglutide, an incretin mimetic, was found to be safe and more effective in glycemic control and body weight loss, than 1.0 mg of semaglutide, according to a study published in ‘The Lancet Diabetes & Endocrinology’. This study was conducted among 961 participants, to test the safety, efficacy, and potential benefits of a higher dose of semaglutide in glycemic control, compared to the conventionally used dose.

The key results were as follows:

• Lower glycated hemoglobin or hemoglobin A1C (HbA1c) in the group taking 2.0mg of semaglutide than the group taking 1.0 mg semaglutide.
• Higher rate of weight loss in the group taking 2.0 mg of semaglutide than the group taking 1.0 mg dose of semaglutide.
• Serious adverse events were similar between both 1.0 mg and 2.0mg semalglutide treatment groups, indicating similar safety profile.

In conclusion, the authors of this study found that semaglutide 2.0 mg was superior to 1.0 mg in treatment outcomes and had similar safety profile. This provides : good option for intensification of treatment for patients on semaglutide, who may need additional glycaemic control.